Sugi Predict

Sugi Predict / Compounds / SCHEMBL7519043

SCHEMBL7519043

SCHEMBL7519043

O=C(O)N1CCC(OCCO)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LIPG Q9Y5X9 1/20 0.39
▸ NAMPT P43490 1/20 0.36
▸ NPC1 O15118 1/20 0.33
▸ LSS P48449 2/20 0.33
▸ F2 P00734 6/20 0.32
▸ PRSS1 P07477 6/20 0.32
▸ ITGB3 P05106 2/20 0.32
▸ ITGA2B P08514 2/20 0.32
▸ PIK3CA P42336 1/20 0.31
▸ GRIN2D O15399 1/20 0.31
▸ GRIN3B O60391 1/20 0.31
▸ GRIN1 Q05586 1/20 0.31
▸ GRIN2A Q12879 1/20 0.31
▸ GRIN2B Q13224 1/20 0.31
▸ GRIN2C Q14957 1/20 0.31
▸ GRIN3A Q8TCU5 1/20 0.31
▸ TEAD1 P28347 1/20 0.31
▸ TEAD3 Q99594 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22835940 0.89 LIPG (0.42) LIPGNAMPT
SCHEMBL16414502 0.89 LIPG (0.42) LIPGNAMPT
SCHEMBL30267164 0.89 NAMPT (0.40) LIPGNAMPTNPC1LSSF2
SCHEMBL22835620 0.89 LIPG (0.42) LIPGNAMPT
SCHEMBL21405513 0.87 LIPG (0.34) LIPGNAMPT
SCHEMBL485207 0.83 ITGB3 (0.42) LIPGITGB3ITGA2B
SCHEMBL6134492 0.83 TAAR1 (0.42) LIPGNAMPTLSSF2PRSS1
SCHEMBL11472234 0.83 EPHX2 (0.39) LIPG
SCHEMBL15207981 0.81 NAMPT (0.34) NAMPTNPC1LSSF2PRSS1
SCHEMBL5270128 0.80 LIPC (0.42) LIPGNAMPTNPC1LSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 — — US disclosed
CN-115803030-A Compounds and methods for KRAS-targeted degradation 阿维纳斯企业公司 2023-03-14 — — CN disclosed
EP-3861000-A1 THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE Genzyme Corporation (US) 2021-08-11 — — EP disclosed
WO-2020072504-A1 THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE GENZYME CORPORATION (US) 2020-04-09 — — WO disclosed
EP-2931723-A1 NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND -LACTAMASE INHIBITORS Fedora Pharmaceuticals Inc. (CA) 2015-10-21 — — EP disclosed
WO-2014091268-A1 NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS NAEJA PHARMACEUTICAL INC. (CA) 2014-06-19 — — WO disclosed
US-6492355-B1 Adamantane derivatives ASTRAZENECA AB (SE) 2002-12-10 — — US disclosed
EP-1171432-A1 ADAMANTANE DERIVATIVES AstraZeneca AB (SE) 2002-01-16 — — EP disclosed
WO-2000061569-A1 ADAMANTANE DERIVATIVES ASTRAZENECA AB (SE) 2000-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 LIPG 2233/4885NAMPT 1694/4885NPC1 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.